



European Monitoring Centre
for Drugs and Drug Addiction

Drug-related infectious diseases DRID network

DRID coordination group

22-23 October 2020

EMCDDA - online



The role of the EMCDDA

Our objective

To contribute to a more secure and a healthier Europe

How?

By providing better evidence for decision making and action on drugs

For who?

EU Institutions and national decision-makers

Professionals



The DRID network

A European Network

- EU MS, Norway, Turkey
- Western Balkans (IPA7)
- European Neighbourhood Policy partners (EU4MD)
- ECDC, WHO
- External experts



**Diversity of experience
and expertise**

2020 Publications - www.emcdda.europa.eu



Implications of COVID-19 for people who use drugs and drug service providers (March 2020)

COVID-19 is a major global health threat. People who use drugs face the same risks as those of the general population and therefore need to be aware of the appropriate advice to reduce their risk of infection. They can be exposed to additional risks, however, that require developing assessment and...



COVID-19 resource page (May 2020)

On this page, the EMCDDA has compiled examples of advice being issued to people who use drugs and service providers by some national bodies and different associations, networks and NGOs. This resource is online only and may be accessed here >>



Impact of COVID-19 on drug services and help-seeking in Europe (May 2020)

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug services in Europe, the European Monitoring Centre for...



Technical reports

Drug-related infectious diseases in Europe: Update from the EMCDDA expert network, 2020

May 2020

This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while highlighting some of the current innovative responses to...



Impact of COVID-19 on patterns of drug use and harms (June 2020)

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people who use drugs in Europe, the EMCDDA instigated a mixed-...



European Drug Report 2020: Trends and Developments (September 2020)

This report provides a comprehensive analysis of patterns emerging across Europe in the areas of drug supply, illicit drug use and associated public health themes. National data sets are also provided across themes and on key harm-reduction interventions. The report is available in English...



Meeting Agenda – sharing action-oriented information


Day 1 (8.30-12.30 GMT+1)

1. COVID-19 direct and indirect impact on drug users
2. Monitoring the progress towards HIV & viral hepatitis Sustainable Development Goals for PWID
3. Evidence based-interventions



Day 2 (8.30-11.00 GMT+1)

4. Outbreaks of infectious diseases among drug users: detection, risk factors, interventions
5. Monitoring methods: city-level RDS and continuous surveillance



General

- Thank you for your abstracts and feedback
- Thank you for speakers
- Kindly keep time limits
- Question time after each presentation and at the end of the session
- 10 min break between sessions if time permits
- Agreement for uploading of presentations



Online conference system

- Kindly make sure we can see your full name
- Please stay on « mute » when not presenting
- To ask a question/make a comment, 2 options:
 - Use the chat box
 - Press the « Raise hand » button
- If the connection goes slow: turn off your camera

